Trv Gp Iii, LLC Revolution Medicines, Inc. Transaction History

Trv Gp Iii, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.68 - $25.53 $35.4 Million - $51.1 Million	-2,000,000 Reduced 55.49%	1,604,130 $38.2 Million
Q3 2022 Nov 03, 2022	SELL	$17.46 - $26.0 $26.2 Million - $39 Million	-1,500,000 Reduced 29.39%	3,604,130 $71.1 Million
Q2 2022 Aug 12, 2022	SELL	$14.54 - $27.17 $6.11 Million - $11.4 Million	-419,901 Reduced 7.6%	5,104,130 $99.5 Million
Q1 2021 May 12, 2021	SELL	$37.21 - $54.43 $55.8 Million - $81.6 Million	-1,500,000 Reduced 21.36%	5,524,031 $253 Million
Q4 2020 Feb 16, 2021	SELL	$30.19 - $45.49 $30.2 Million - $45.5 Million	-1,000,000 Reduced 12.46%	7,024,031 $278 Million
Q3 2020 Nov 06, 2020	SELL	$22.61 - $34.8 $22.6 Million - $34.8 Million	-1,000,000 Reduced 11.08%	8,024,031 $279 Million
Q1 2020 May 11, 2020	BUY	$20.0 - $34.08 $180 Million - $308 Million	9,024,031 New	9,024,031 $198 Million

299

179M

920K

1.06M

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.63B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Trv Gp Iii, LLC, based on Form 13F filings with the SEC.

Stay updated on Trv Gp Iii, LLC with notifications on news.